Baidu
map

Arch Immunol Ther Exp (Warsz):过敏性鼻炎儿童中的外周血调节性T细胞变化分析

2017-12-27 AlexYang MedSci原创

关于在小儿过敏性疾病中调节性T(Treg)细胞的研究,尤其是关于过敏性鼻炎(AR)的非常少,距离清晰的了解还很远。最近,有研究人员评估了CD4+CD25+Foxp3+ (CD4+Tregs) 和CD8+CD25+highFoxp3+ (CD8+Tregs) 调节性T细胞在AR儿童外周血中的频率情况。研究包括了60名AR儿童和40名健康儿童的新鲜全血样本。研究人员通过流式细胞仪检测了CD4+ 和CD

关于在小儿过敏性疾病中调节性T(Treg)细胞的研究,尤其是关于过敏性鼻炎(AR)的非常少,距离清晰的了解还很远。最近,有研究人员评估了CD4+CD25+Foxp3+ (CD4+Tregs) 和CD8+CD25+highFoxp3+ (CD8+Tregs) 调节性T细胞在AR儿童外周血中的频率情况。

研究包括了60名AR儿童和40名健康儿童的新鲜全血样本。研究人员通过流式细胞仪检测了CD4+ 和CD8+的频率,还测量了血清中lgE的总浓度。研究发现,与健康对照组相比,AR儿童中的CD4+调节性T细胞 和CD8+调节性T细胞的频率显著减少(分别为p=0.041, p=0.011)。更多的是,在CD4+CD25+high和 CD8+CD25+high细胞中 Foxp3+的表达在病人组中要比对照显著性更低。另外,研究人员还发现CD4+调节性T细胞和总lgE浓度具有显著的负相关关系(p<0.01)。

最后,研究人员指出,他们的研究阐释了CD4+调节性T细胞和CD8+调节性T细胞在患有AR的儿童中的比例显著减少。这表明了调节性T细胞的减少也许表明了AR儿童中T细胞群体的一个缺陷。更进一步的研究需要来充分的鉴定在AR儿童中调节性T细胞的临床相关性。

原始出处:

Saad K, Zahran AM, Elsayh KI et al. Variation of Regulatory T Lymphocytes in the Peripheral Blood of Children with Allergic Rhinitis. Arch Immunol Ther Exp (Warsz). 18 Dec 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046922, encodeId=50852046922ba, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 03 11:45:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578534, encodeId=db2c15e853480, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Fri Dec 29 11:45:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273319, encodeId=5c142e3319dd, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 28 22:23:06 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273066, encodeId=b9ad2e3066f6, content=不错的文章.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Dec 27 22:55:16 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273051, encodeId=f67e2e3051f5, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Dec 27 22:20:54 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273030, encodeId=ee692e30306b, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Dec 27 21:39:37 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046922, encodeId=50852046922ba, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 03 11:45:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578534, encodeId=db2c15e853480, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Fri Dec 29 11:45:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273319, encodeId=5c142e3319dd, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 28 22:23:06 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273066, encodeId=b9ad2e3066f6, content=不错的文章.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Dec 27 22:55:16 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273051, encodeId=f67e2e3051f5, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Dec 27 22:20:54 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273030, encodeId=ee692e30306b, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Dec 27 21:39:37 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046922, encodeId=50852046922ba, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 03 11:45:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578534, encodeId=db2c15e853480, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Fri Dec 29 11:45:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273319, encodeId=5c142e3319dd, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 28 22:23:06 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273066, encodeId=b9ad2e3066f6, content=不错的文章.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Dec 27 22:55:16 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273051, encodeId=f67e2e3051f5, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Dec 27 22:20:54 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273030, encodeId=ee692e30306b, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Dec 27 21:39:37 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
    2017-12-28 smartxiuxiu

    有用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2046922, encodeId=50852046922ba, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 03 11:45:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578534, encodeId=db2c15e853480, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Fri Dec 29 11:45:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273319, encodeId=5c142e3319dd, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 28 22:23:06 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273066, encodeId=b9ad2e3066f6, content=不错的文章.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Dec 27 22:55:16 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273051, encodeId=f67e2e3051f5, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Dec 27 22:20:54 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273030, encodeId=ee692e30306b, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Dec 27 21:39:37 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
    2017-12-27 131****2916

    不错的文章.值得推荐

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2046922, encodeId=50852046922ba, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 03 11:45:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578534, encodeId=db2c15e853480, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Fri Dec 29 11:45:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273319, encodeId=5c142e3319dd, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 28 22:23:06 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273066, encodeId=b9ad2e3066f6, content=不错的文章.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Dec 27 22:55:16 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273051, encodeId=f67e2e3051f5, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Dec 27 22:20:54 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273030, encodeId=ee692e30306b, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Dec 27 21:39:37 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
    2017-12-27 thlabcde

    好资料学习了!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2046922, encodeId=50852046922ba, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Oct 03 11:45:00 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578534, encodeId=db2c15e853480, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Fri Dec 29 11:45:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273319, encodeId=5c142e3319dd, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 28 22:23:06 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273066, encodeId=b9ad2e3066f6, content=不错的文章.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Wed Dec 27 22:55:16 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273051, encodeId=f67e2e3051f5, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Dec 27 22:20:54 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273030, encodeId=ee692e30306b, content=不错的文章.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Dec 27 21:39:37 CST 2017, time=2017-12-27, status=1, ipAttribution=)]
    2017-12-27 1e1b8538m79(暂无匿称)

    不错的文章.值得拥有

    0

相关资讯

Clin Transl Allergy:屋尘螨皮下免疫治疗在老年过敏性鼻炎患者中的疗效和安全性证据

过敏原特异性免疫疗法(AIT)在老年病人中是具有争议的,并且到目前为止在该人群中能够支持该种疗法安全性和疗效方面的证据依据很少。最近,有研究人员评估了屋尘螨过敏原AIT疗法在年龄大于65岁且患有过敏性鼻炎(AR)和对屋尘螨过敏的患者中的疗效和安全性。研究包括了58名只对屋尘螨敏感的老年病人,并且被随机分配到数目匹配的两个平行小组中,并且进行了如下的干预:利用PURETHAL螨虫或者安慰剂进行为期2

Laryngoscope:鼻内接种磷酰胆碱能够抑制过敏性鼻炎

鼻内接种磷酰胆碱(PC)能够减少免疫球蛋白(lg)E的产生。然而,它对过敏性鼻炎(AR)产生的影响还未知。最近,有研究人员评估了PK-KLH的影响,并且还探究了在小鼠模型中对AR产生的影响。研究包括了45只雌性BALB/c小鼠,并且分成3个小组。包括前处理使用PC-KLH鼻内给药,之后进行卵清蛋白(OVA)的腹膜内敏化左右和鼻粘膜挑战(组A);没有用PC-KLH处理但用OVA进行腹膜内敏化左右和鼻

BMC Med Genet:FOXO3中的一个内含子单核苷酸多态性与哮喘和过敏性鼻炎相关

哮喘和过敏性鼻炎均是呼吸系统疾病,并且造成了显著的全球负担。FOXO3基因参与了许多呼吸系统疾病的发病病因。最近,有研究人员评估了rs13217795,一个内含子FOXO3单核苷酸多态性与哮喘和过敏性鼻炎之间的关系。研究人员设计的研究为案例-案例-对照遗传相关性研究,并且利用PCR-RFLP方法进行了基因分型。最终研究群体包括了94名对照,124名哮喘患者和110名过敏性鼻炎患者。疾病外显率的一般

Allergol Int:在健康和哮喘患者中,血清骨膜蛋白与身体质量指数和过敏性鼻炎相关

许多研究在哮喘患者中尝试鉴定了与血清骨膜蛋白水平相关的因素。然而,这些研究的结果主要基于对具有高嗜酸性粒细胞数目患者的研究,这也许会对与血清骨膜蛋白水平相关的其他因素的鉴定造成干扰。最近,有研究人员确定了在健康受试者中,与血清骨膜蛋白水平相关的因素。研究人员同样在哮喘患者中评估了一些因素,从而认知它们在哮喘中的作用。研究测量了230健康受试者的血清骨膜蛋白水平。感兴趣的临床因素包括了身体质量指数(

Eur Arch Otorhinolaryngol:在过敏性鼻炎儿童中,白介素-33能够促进辅助T细胞类型-2/17炎症反应

白介素-33是最近才被描述的细胞激素,并且与辅助T细胞类型2(Th2)调控的疾病有关。然而,它在儿童过敏性鼻炎(AR)发病机理中的调控角色仍旧需要进一步的鉴定。最近,有研究人员进行了旨在评估IL-33在患有AR儿童中的表达情况以及作用。研究包括了40名患有AR的儿童,并且还包括了20名健康的对照,并通过酶联免疫反应试验(ELISA)分别检测了IL-33和Th细胞激素在血清和鼻腔灌洗液中的产生情况。

Allergy Asthma Immunol Res:过敏性鼻炎的中药治疗研究

中草药(CHM)在中国被广泛的应用于过敏性鼻炎(AR)的治疗。然而,一些研究关于中草药治疗过敏性鼻炎的疗效,产生了相互矛盾的结果。最近,有研究人员进行那个了随机临床试验(RCTs)的元分析来评估CHM的相关疗效。研究人员就在AR病人的治疗中,利用RCTs比较CHM疗效和安慰剂方面,系统性的查询了到2017年3月份的PubMed、Medine和Springer电子数据库。总的鼻症状和生活质量通过混样

Baidu
map
Baidu
map
Baidu
map